Merkel Cell Carcinoma: Brief Summary
Merkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous neuroendocrine cancer with mortality rates exceeding melanoma, characterized by rapid growth, early metastasis, and a dramatically increasing incidence of 5-10% per year. 1
Disease Characteristics
Epidemiology and Incidence:
- Approximately 2,488 cases diagnosed annually in the United States, representing less than 1% of all cutaneous malignancies 1, 2
- Incidence has increased 5.4-fold over 18 years, with continued annual increases of 5-10% 1
- Predominantly affects elderly Caucasians (>90% over age 50, >76% are ≥65 years, ≥95% are Caucasian) 1
Clinical Behavior and Prognosis:
- MCC is exceptionally aggressive: 63% of primary lesions grow rapidly within 3 months prior to diagnosis, 26-36% present with lymph node involvement, and 6-16% present with distant metastatic disease 1
- At least half of all patients develop lymph node metastases and nearly one-third develop distant metastases 1
- Recurrence develops in 25-50% of all cases 1
- Five-year survival ranges from 41-77% depending on stage at presentation, with metastatic disease showing <15% five-year survival 1, 3
- Mortality rate exceeds that of melanoma 1
Pathogenesis and Risk Factors
Two Distinct Oncogenic Pathways:
- Merkel cell polyomavirus (MCPyV)-positive tumors (80% of cases): Associated with viral protein expression and better prognosis 4, 2, 5
- UV-induced tumors (20% of cases): Characterized by higher mutational burden and C-to-T mutations indicative of UV damage 1, 2
Major Risk Factors:
- Sun exposure and UV radiation (81% occur on sun-exposed areas, 29-48% on head and neck) 1
- Advanced age 1
- Immunosuppression (organ transplants, chronic lymphocytic leukemia, HIV infection) with worse survival outcomes 1
- Caucasian ethnicity 1
Clinical Presentation
- Typically manifests as a rapidly growing red nodule or plaque on sun-exposed areas 2
- Frequently misdiagnosed due to innocuous appearance on clinical examination 3
- Often diagnosed at advanced stages due to delayed recognition 3
Diagnostic Approach
Histopathology and Immunohistochemistry:
- Small-cell neuroendocrine appearance on histology 2
- CK20 positivity and TTF-1 negativity confirm diagnosis 2
- Merkel cell polyomavirus can be used as a biomarker 1
Staging Workup:
- Baseline whole body imaging recommended to rule out regional and distant metastasis 2
- Sentinel lymph node biopsy recommended in all patients without clinically detectable lymph nodes or distant metastasis 2
Treatment Approach
Localized Disease:
- First-line treatment is surgical excision with postoperative margin assessment followed by adjuvant radiation therapy 2
- Sentinel lymph node biopsy should be performed in appropriate candidates 2
- For micrometastatic nodal involvement: adjuvant RT alone, potentially combined with complete lymph node dissection 2
- For macroscopic nodal involvement: complete lymph node dissection potentially followed by postoperative RT 2
Advanced/Metastatic Disease:
- Immunotherapy with PD-1/PD-L1 inhibitors (avelumab, pembrolizumab, nivolumab, retifanlimab) is now standard first-line systemic treatment for advanced MCC 1, 4, 2
- These agents demonstrate durable antitumor activity with response rates comparable to chemotherapy but with more enduring responses 4
- Adjuvant nivolumab has proven superiority to observation in the adjuvant setting 4
- Chemotherapy can be used when patients fail to respond or are intolerant to anti-PD-(L)1 immunotherapy, though historically yields only 3 months median response duration 4, 6
Key Clinical Caveat: More than 50% of patients experience primary or secondary failure to immunotherapy, with no satisfactory second-line options currently available 5. Ongoing trials are evaluating dual immunotherapy (ipilimumab/nivolumab), novel immune checkpoint inhibitors, targeted therapies, cellular therapies, vaccines, and oncolytic virus therapies for refractory disease 3, 5.